RxDoctor Payments Data

Shyam Vyas, MD

Psychiatry · Nacogdoches, TXNPI 1992850184

Payments from drug & device makers

$6,357in general payments, 2019–2025

Across 183 payments — averaging $34.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corium, LLC$3K
  • Ironshore Pharmaceuticals Inc.$909
  • AbbVie$393
  • Tris Pharma Inc$347
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
  • Collegium Pharmaceutical, Inc.$222
  • plus $982 from 15 others

What the payments were for

  • Consulting fees$1,62025%
  • Travel & lodging$1,05117%
  • Food & beverage$3,68658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,357 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$29,764
Medicare patients
73
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$22,108
VyvanseLisdexamfetamine Dimesylate14$5,158
AzstarysSerdexmethylphen/Dexmethylphen12$4,808
Venlafaxine Hcl ErVenlafaxine Hcl215$3,268
Quetiapine Fumarate157$2,639
Lurasidone Hcl45$2,347
Lisdexamfetamine Dimesylate12$2,282
Aripiprazole41$2,268
Bupropion XlBupropion Hcl91$2,223
Desvenlafaxine Succinate ErDesvenlafaxine Succinate30$1,507
Duloxetine Hcl83$1,410
Trazodone Hcl200$1,379
Buspirone Hcl83$1,376
Bupropion Hcl SrBupropion Hcl90$1,291
Mirtazapine94$984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$182$22,10814 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$130$5,15814 claims
Corium, LLCAzstarys$3,275$4,80812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Nacogdoches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →